Protalix BioTherapeutics/$PLX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Protalix BioTherapeutics
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
Ticker
$PLX
Sector
Primary listing
AMEX
Employees
226
Headquarters
Website
PLX Metrics
BasicAdvanced
$154m
9.89
$0.19
-0.01
-
Price and volume
Market cap
$154m
Beta
-0.01
52-week high
$3.19
52-week low
$1.32
Average daily volume
770k
Financial strength
Current ratio
3.153
Quick ratio
1.972
Long term debt to equity
10.484
Total debt to equity
12.615
Interest coverage (TTM)
14.36%
Profitability
EBITDA (TTM)
21.314
Gross margin (TTM)
45.24%
Net profit margin (TTM)
20.07%
Operating margin (TTM)
25.91%
Effective tax rate (TTM)
20.42%
Revenue per employee (TTM)
$340,000
Management effectiveness
Return on assets (TTM)
14.04%
Return on equity (TTM)
27.27%
Valuation
Price to earnings (TTM)
9.886
Price to revenue (TTM)
1.984
Price to book
2.29
Price to tangible book (TTM)
2.29
Price to free cash flow (TTM)
11.662
Free cash flow yield (TTM)
8.57%
Free cash flow per share (TTM)
0.164
Growth
Revenue change (TTM)
27.80%
Earnings per share change (TTM)
323.88%
3-year revenue growth (CAGR)
22.91%
10-year revenue growth (CAGR)
36.70%
3-year earnings per share growth (CAGR)
-14.30%
10-year earnings per share growth (CAGR)
-28.76%
What the Analysts think about PLX
Analyst ratings (Buy, Hold, Sell) for Protalix BioTherapeutics stock.
PLX Financial Performance
Revenues and expenses
PLX Earnings Performance
Company profitability
PLX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Protalix BioTherapeutics stock?
Protalix BioTherapeutics (PLX) has a market cap of $154M as of May 20, 2026.
What is the P/E ratio for Protalix BioTherapeutics stock?
The price to earnings (P/E) ratio for Protalix BioTherapeutics (PLX) stock is 9.89 as of May 20, 2026.
Does Protalix BioTherapeutics stock pay dividends?
No, Protalix BioTherapeutics (PLX) stock does not pay dividends to its shareholders as of May 20, 2026.
When is the next Protalix BioTherapeutics dividend payment date?
Protalix BioTherapeutics (PLX) stock does not pay dividends to its shareholders.
What is the beta indicator for Protalix BioTherapeutics?
Protalix BioTherapeutics (PLX) has a beta rating of -0.01. This means that it has an inverse relation to market volatility.